Market Research Report
Global Markets for Orphan Drugs
|Global Markets for Orphan Drugs|
Published: July 23, 2021
Content info: 128 Pages
Delivery time: 1-2 business days
The global orphan drugs market should reach $248.2 billion by 2026 from $190.8 billion in 2021 at a compound annual growth rate (CAGR) of 5.4% for the forecast period of 2021 to 2026.
The biological orphan drugs segment of the global orphan drugs market is expected to grow from $141.8 billion in 2021 to $184.0 billion in 2026 at a CAGR of 5.3% for the forecast period of 2021 to 2026.
The non-biological orphan drugs segment of the global orphan drugs market is expected to grow from $48.9 billion in 2021 to $64.2 billion in 2026 at a CAGR of 5.6% for the forecast period of 2021 to 2026.
The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections and market shares. Technological issues include the latest trends and developments.
This report covers the U.S. and European markets, and emerging global markets such as India, Japan, China, Singapore, Taiwan, Korea, Canada, Brazil, Africa, Australia and New Zealand.
This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape.